This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AC-150
AC-150 is an ophthlamic formulation for the potential treatment of allergic conjunctivitis.
Aciex and Nicox
In July 2014, Nicox announced it has signed an agreement to acquire all of the outstanding equity of Aciex Therapeutics. The completion of the acquisition remains subject to the approval of Nicox’s shareholders and other customary conditions.
Under the proposed acquisition, Nicox will acquire all outstanding shares of Aciex on a cash-free debt-free basis through a reverse triangular merger, governed by US laws and regulations. Aciex shareholders will receive an upfront payment of $65 million entirely in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights (CVRs) giving rights to Nicox shares based on the potential US FDA approval(s) of AC-170 and of two additional undisclosed products within a pre-determined period.
In October 2014, Nicox announced the completion of the acquisition of Aciex Therapeutics.
Additional information available to subscribers only: